Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022GlobeNewsWire • 03/30/22
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerGlobeNewsWire • 02/09/22
KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar TodayInvestorPlace • 12/23/21
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United KingdomGlobeNewsWire • 12/21/21
EXCLUSIVE: Pasithea Expands Its Footprint With Second Ketamine Therapy Clinic In UKBenzinga • 12/21/21
Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq RulesGlobeNewsWire • 11/29/21
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq RulesGlobeNewsWire • 11/24/21
KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic TodayInvestorPlace • 11/23/21
Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.GlobeNewsWire • 11/23/21
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion TherapyGlobeNewsWire • 10/27/21
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United KingdomGlobeNewsWire • 10/14/21
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug DiscoveryBenzinga • 10/11/21
Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development AgreementGlobeNewsWire • 10/11/21